NEWS
Dr Nasser Azli joins Tollys Scientific Advisory Board
Nasser Azli is a medical oncologist with over 30 years of academic and pharmaceutical experience. As an expert in clinical oncology and drug development, Nasser Azli is a highly valuable addition to our Scientific Advisory Board, particularly in view of the upcoming first clinical trials of our drug candidate TL-532.
Tollys moves its headquarters
The new 300 sqm headquarters will support Tollys’ growth by offering all the features expected by biotech companies. This move to our new headquarters allows our team to work not only in our own research laboratories but also near the scientific and medical communities. This new space is specifically designed for biotech companies and will support our developments very efficiently.
Tollys presents scientific data supporting preclinical proof of concept for TL-532, its cancer immunotherapy drug candidate
Doctors Marc Bonnin and Sylvain Thierry will present Tollys’ results at the EACR 2021 Congress, which will take place from June 9 -12. We’re proud to be able to share this data, which proves the potential of this specific TLR3 agonist in immuno-oncology, in particular by releasing tumor-specific antigens.
Tollys earns ‘Best-in-class therapeutic innovation’ award from MATWIN for its drug candidate TL-532
Confirmation by MATWIN’s panel of scientific and industry experts of therapeutic potential of TL-532 major boost for Tollys, supports moving flagship product towards clinical phase.
Tollys appoints Amina Zinaï, MD, as head of clinical development
Drawing on her expertise, Dr. Zinaï will be supporting Tollys in its early clinical developments.

Tollys
Cutting-Edge Cancer Immunotherapy
Office
60F avenue Rockefeller
69008 Lyon, FRANCE